期刊文献+

B7家族及其受体PD-1在人NK/T细胞淋巴瘤中的表达及临床意义 被引量:11

The expression and clinical significance of B7 family molecules and their receptor PD-1 in human NK/T-cell lymphoma
下载PDF
导出
摘要 目的:探讨B7家族及其受体(programmed death-1,PD-1)在人NK/T细胞淋巴瘤(NKTL)中的表达及临床意义。方法:荧光定量PCR(real time fluorescence quantitative PCR,RQ-PCR)及免疫组织化学SP法检测PD-1及B7家族PD-L1、PD-L2在人NKTL细胞系(SNK-6、YTS)及NKTL组织中的表达,并分析其与临床病理学参数及临床疗效之间的关系。结果:PD-L1和PD-L2mRNA在SNK-6、YTS中的表达明显高于正常NK细胞。PD-L1和PD-L2蛋白在NKTL组织中的表达阳性率(分别为60.0%、63.3%)明显高于鼻炎组织(22.2%、16.7%);NKTL组织中PD-1+肿瘤浸润T淋巴细胞(TIL)数与PD-L1、PD-L2的表达均呈负相关;PD-L1和PD-L2的表达水平与分期均呈正相关,PD-L1与LDH、Ki-67水平呈正相关,PD-L1与IPI评分呈负相关,PD-L1及PD-L2与其他临床病理学参数无显著相关性。PD-L1与治疗疗效呈负相关,而PD-L2与治疗疗效无明显相关性。结论:B7家族及其受体PD-1在人NKTL中高表达且具有一定的临床意义,PD-L/PD-1信号途径可能参与了NKTL的免疫逃逸,有望成为人NK-TL免疫治疗的新靶点。 Objective: To investigate the expression and clinical significance of B7 family molecules and their receptor PD-1( programmed death-l) in human NK/T-cell lymphoma (NKTL). Methods: Real time fluorescence quantitative PCR (RQ-PCR) and Immunohistochemistry SP method were used to detect the expression levels of PD-1 and B7 family molecules (PD-L1 and PD-L2) in human NKTL cell lines (SNK-6 and YTS) and NKTL tissues .The correlation between these proteins and Clinical histopathological parameters and curative effect were analyzed subsequently. Results: The expression levels of PD-L1 and PD-L2 mRNA in SNK-6 and YTS were significantly higher than that in normal NK cells.. The expression of PD-L1 and PD-L2 proteins in human NKTL tissues (60.0%, 63.3%) and curative effect were significantly increased compared with rhinitis tissues (22.2%, 16.7%);furthermore, the mean count of PD-1 +Tumor-infiltrating T lymphocytes(TIL) was inversely correlated with PD-L1 and PD-L2 protein expression levels in NKTL tissues.. The expression of PD-L1 and PD-L2 showed a positive correlation with clinical stage.. PD-L1 expression was also positively correlated with LDH, Ki-67 level and was negatively correlated with IPI score. However, there were no significant correlation between PD-L1 and PD-L2 with other Clinical histopathological parameters..-PD-L1 expression was negatively correlated with curative effect. However, there was no correlation between PD-L2 expression and curative effect. Conclusion: B7 family molecules and their receptor PD-1 are overexpressed in human NKTL and have greatly clinical significance.PD-L/PD-1 pathway may involved in the tumor immune escape in human NKTL, and it is expected to be a novel target for immunotherapy of human NKTL.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2014年第6期363-367,共5页 Chinese Journal of Clinical Oncology
基金 国家自然科学基金项目(编号:81172118)资助~~
关键词 淋巴瘤PD-L1 PD-L2 PD-1 NK细胞 lymphoma, PD-L1, PD-L2, PD-1, NK cell
  • 相关文献

参考文献4

二级参考文献30

  • 1宋敏,白云,王艳艳,熊加祥,杨旭冉,罗娜.小胶质细胞表达B7-H1及LPS刺激对其表达影响的研究[J].免疫学杂志,2006,22(3):243-246. 被引量:3
  • 2Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-HI promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 2002, 8:793-800.
  • 3Strome SE, Dong H, Tamura H, et al. BT-HI blockade auguments adoptive T-cell immunotherapy for squamous cell carcinoma, Cancer Res, 2003, 63:6501-6505.
  • 4Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD-1 expression. Clin Cancer Res, 2004, 10:5094-5100.
  • 5Ohigashil Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res, 2005, 11:2947-2953.
  • 6Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res, 2007, 13 : 2151-2157.
  • 7Cho Y, Miyamoto M, Kato K, et al. CD4^+ and CD8^+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res, 2003, 63 : 1555-1559.
  • 8Ropponen KM, Eskelinen MJ, Lipponen PK, et al. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol, 1997, 182:318-324.
  • 9Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol, 2005, 23:515-548.
  • 10Dong H, Zhu G, Tamada K, et al. B7-H1 ,a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 1999, 5:1365-1369.

共引文献79

同被引文献68

  • 1施勤,邓敏,顾永平,谢芳,李文香,张学光.OX40、OX40L分子在乳腺癌中的表达及其临床意义[J].中国现代医药杂志,2004,6(6):1-3. 被引量:4
  • 2黄迪君,王再谟,周志昆,金荣疆,高虹,万大凤,张安仁.麦粒灸加叩刺拔罐法治疗类风湿性关节炎120例[J].成都中医药大学学报,1996,19(1):17-19. 被引量:18
  • 3柴立勋,孙克林,郭黎平,张宏图,陆士新.食管鳞癌中Ezrin和CD44-v6的表达及其临床意义[J].中华肿瘤杂志,2007,29(9):685-688. 被引量:26
  • 4Shimauchi T, Kabashima K, Nakashima D, et al. Augmented ex-pression of programmed death-1 in both neoplastic and non-neo-plastic CD4+ T-cells in adult T-cell leukemia/lymphoma[ J] . Int JCancer, 2007, 121(12) : 2585-2590.
  • 5Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1promotes T-cell apoptosis : a potential mechanism of immune eva-sion[j]. Nat Med, 2002,8(8) : 793-800.
  • 6Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade withnivolumab in relapsed or refractory Hodgkin's lymphoma[ J]. NEngl J Med, 2015, 372(4): 311-319.
  • 7Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety andpharmacokinetic study of CT-011,a humanized antibody interactingwith PD-1,in patients with advanced hematologic malignancies[J]. Clin Cancer Res, 2008, 14(10) : 3044-3051.
  • 8Armand P, Nagler A, Weller EA, et al. Disabling immune toler-ance by programmed death-1 blockade with pidilizumab after autol-ogous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase Q trial [ J ] . JClin Oncol, 2013,31(33) : 41994206.
  • 9Moskowitz CH, Ribrag V,Michot JM, et al. PD-1 blockade withthe monoclonal antibody Pembrolozumab ( MK-3475 ) in patientswith classical hodgkin lymphoma after Brentnximab vedotin failure :preliminary results from a phase lb study ( KEYN0TE-013 ) [ J].Blood, 2014, 124: 290.
  • 10Lesokhin AM,Ansell SM, Armand P, et al, Preliminary results ofa phase I study of nivolumab ( BMS-936558) in patients with re-lapsed or refractory lymphoid malignancies [ J ]. Blood, 2014,124: 291.

引证文献11

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部